Pricing Log in Create free account
Friday 6 November 2026 Export SCYX’s income statement to Excel — free account

SCYNEXIS, Inc.

SCYX Healthcare Drug Manufacturers Specialty & Generic

SCYNEXIS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 million, up 449.9% from fiscal 2024.

Revenue
−8.56%
EPS
+156.3%
Free cash flow
−98.6%

Quarter to June 2026, against a year earlier

3.45 0.15 +4.55%
Market cap
$32.8M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
5/9
Altman Z
−7.02
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — 1 — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 19.15%

Capital & Financial Ratios $m

Size
Market Cap 32.84
Revenue ttm 20.58
Net income ttm (10.23)
Free cash flow ttm (13.31)
Net debt Q (54.16)
Valuation
P/E 0.00
Forward P/E (1.30) (negative: loss-making)
Price / sales 1.91
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.59
Financial health
Current ratio Q 9.65 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (49.77)
Growth
Revenue growth Q −8.56% (below 0%: shrinking)
Operating income growth Q +18.68% (above 0%: growing)
EPS, this year −113.97% (below 0%: weak)
EPS, next year A +20.45% (at or above 15%: strong)
Revenue, next year A −96.99% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −15.40% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.5×, against a ten-year median of 12.1×; over the ten years it ranged from −36.3× in 2018 to 380× in 2020.
P/S against its own 10 years 11.73%
10-year low 10-year high
P/B against its own 10 years 0.15%
10-year low 10-year high
EV/Sales against its own 10 years 9.46%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 75 60 40 54
Receivables — — — —
Inventory — — — —
Other 22 10 — —
102 72 40 56
2023 2024 2025 Q'26
Payables 7 5 2 3
ST’ Debt — — — —
Other 0 — — —
16 24 6 6

Compound Annual Growth %

10y 5y 3y
Sales 32.28% 179.40% 59.35%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 1.64% 16.76% 148.11%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.40 Actual −0.32

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −1.68 −1.36 Beat by 0.32
Q4 FY25 2.32 2.00 Miss by 0.32
Q1 FY26 −0.80 −3.36 Miss by 2.56
Q2 FY26 −0.40 −0.32 Beat by 0.08
Q3 FY26 −0.40 — Reports 4 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (3.36) 0.63 — — —
’25 (0.88) (1.12) (1.36) 2.00 (1.36)
’24 0.08 (2.40) (0.48) (0.72) (3.52)
’23 (5.68) 19.68 (0.32) (3.12) 11.12
’22 (1.44) (2.48) (4.96) (2.32) (11.76)
’21 (1.41) (1.76) (0.17) (8.40) (10.00)
’20 (5.60) (5.12) 0.54 (31.36) (41.20)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — 0 — — —
’25 0 1 0 19 21
’24 1 1 1 1 4
’23 1 131 2 6 140
’22 1 1 2 2 5
’21 12 — 1 1 13
’19 0 0 — 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (8) (15) — — —
’25 (7) (7) (9) 18 (5)
’24 (4) (11) 1 (10) (24)
’23 (19) 74 12 (8) 60
’22 (16) (19) (23) (23) (80)
’21 (1) (12) (17) (26) (55)
’20 (14) (9) (10) (17) (49)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (8) (15) — — —
’25 (7) (7) (9) 18 (5)
’24 (4) (11) 1 (10) (24)
’23 (19) 74 12 (8) 60
’22 (16) (19) (23) (23) (80)
’21 (1) (12) (17) (26) (56)
’20 (14) (9) (10) (17) (49)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 0 0 0 0 — 13 5 140 4 21 21 +62.8% 1 7 14 (11.9%)
Gross margin, % 100.00 100.00 100.00 100.00 0.00 97.63 87.66 88.85 100.00 100.00 100.00 0.0 pt
EBT (30) (25) (19) (54) (58) (36) (68) 67 (21) (9) (10) (12.9%)
EBT margin, % (11,668.87) (9,750.97) (7,472.37) (44,388.43) 0.00 (273.14) (1,326.05) 47.94 (564.26) (41.79) (49.74) +11,627.1 pt
Net income (30) (25) (12) (54) (55) (33) (63) 67 (21) (9) (10) (12.9%)
Per share, $
Per share, $ Revenue 1.08 0.77 0.47 0.17 0.00 3.99 0.96 23.43 0.62 3.30 1.74 +13.2%
Earnings (126.40) (75.20) (22.40) (76.80) (41.20) (10.00) (11.76) 11.20 (3.52) (1.36) (2.09) (39.6%)
Cash flow (123.38) (73.45) (51.63) (54.38) (36.83) (16.54) (15.00) 10.06 (3.96) (0.85) (1.13) (42.5%)
Capex (0.11) (0.01) (1.03) 0.00 0.00 (0.36) 0.00 0.00 0.00 0.00 0.00 n/m
Free cash flow (123.50) (73.46) (52.66) (54.38) (36.83) (16.90) (15.00) 10.06 (3.96) (0.85) (1.13) (42.5%)
Book value 146.36 64.04 56.92 18.40 16.98 12.51 0.61 12.20 9.08 7.91 5.66 (27.7%)
Shares, m 0 0 1 1 1 3 5 6 6 6 8 +43.8%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 — 0.00 0.00 1.56 0.00 0.00 0.00 0.2
P/S 251.79 237.26 82.27 274.37 — 12.23 12.05 0.75 15.67 1.53 1.91 98.7
P/B 1.86 2.85 0.68 3.96 — 3.90 18.98 1.45 1.07 0.64 0.59 3.9
EV/Sales 137.65 123.48 (2.48) 76.22 — 7.36 7.71 0.31 6.62 0.84 0.54 39.7
EV/FCF (1.20) (1.29) 0.02 (0.37) — (1.74) (0.49) 0.72 (1.03) (3.27) (0.83) (1.0)
Cash, $m
Cash, $m Operating cash flow (29) (25) (28) (38) (49) (55) (80) 60 (24) (5) (13) (17.3%)
Capex 0 0 (1) — 0 (1) 0 — — — 0 (16.7%)
Free cash flow (29) (25) (29) (38) (49) (56) (80) 60 (24) (5) (13) (17.4%)
Balance, $m
Balance, $m Working capital 56 35 46 41 72 96 61 86 48 35 50 (5.1%)
Net debt (44) (29) (29) (37) (77) (64) (28) (63) (60) (40) (54) (1.1%)
Shareholders’ equity 35 21 31 13 23 41 3 73 55 49 67 +4.0%
Returns, %
Returns, % ROA (54.99) (47.44) (25.18) (97.37) (69.12) (29.56) (60.50) 62.01 (19.44) (11.50) (15.09) +43.5 pt
ROIC 0.00 0.00 (894.48) 0.00 0.00 0.00 0.00 437.60 0.00 (108.43) (110.72) (108.4) pt
ROE (78.13) (89.14) (47.38) (243.47) (309.57) (102.68) (282.34) 175.97 (33.25) (16.48) (18.38) +61.7 pt
People
People Employees 14 19 24 27 38 56 36 29 28 18 — +2.8%
Revenue/emp, $m 0.02 0.01 0.01 0.00 0.00 0.24 0.14 4.83 0.13 1.14 — +58.3%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

SCYNEXIS, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TLPH Talphera, Inc. $52.4M — (loss-making) — (loss-making) −99.60% (below 0%: shrinking) n/m −33.11% (below 0%: shrinking) 100.00% 0.00% Compare
CTOR Citius Oncology, Inc. $46.5M — (loss-making) — — n/m 0.00% 67.07% (583.53%) Compare
ZYBT Zhengye Biotechnology Holding Limited $41.0M — — — — −69.31% (below 0%: shrinking) — — Compare
INCR InterCure Ltd. $39.1M 6.2× — (loss-making) −6.53% (below 0%: shrinking) n/m +389.50% (above 0%: growing) 32.04% 0.00% Compare
SCYX SCYNEXIS, Inc. $32.8M — (loss-making) — (loss-making) −8.56% (below 0%: shrinking) n/m −98.60% (below 0%: shrinking) 100.00% (3,308.51%)
RMTI Rockwell Medical, Inc. $30.6M — (loss-making) — (loss-making) +10.63% (above 0%: growing) n/m −12.92% (below 0%: shrinking) 18.24% (5.97%) Compare
IXHL Incannex Healthcare Inc. $28.5M — (loss-making) — (loss-making) −92.31% (below 0%: shrinking) n/m +327.73% (above 0%: growing) 100.00% 0.00% Compare
SHPH Shuttle Pharmaceuticals Holdings, Inc. $24.0M — (loss-making) — — n/m +82.01% (above 0%: growing) 0.00% 0.00% Compare
CPHI China Pharma Holdings, Inc. $22.8M — (loss-making) — (loss-making) −7.56% (below 0%: shrinking) n/m −113.57% (below 0%: shrinking) 8.82% (150.99%) Compare
Median of peers $34.8M — — −7.56% — −6.46% 32.04% 0.00%

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.54m 947.17k 40.53
2024 2.03m 1.43m 77.56
2023 1.21m 1.49m 142.95

Ownership

Directors and executive officers, together 4.09%
Avidity Partners Management LP 9.99%
Entities affiliated with Great Point Partners LLC 9.99%
Squadron Master Fund LP 9.58%
CVI Investments, Inc. 5.92%
Adage Capital Partners, L.P. 5.47%
Entities affiliated with Propel Bio Management, LLC 5.47%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

SCYNEXIS, Inc. (SCYX) Latest News

5 Nov

Impact 4 · · GlobeNewswire
Impact 3 · · Associated Press Finance
Impact 3 · · GlobeNewswire

22 Oct

Impact 4 · · GlobeNewswire

21 Oct

Impact 4 · · GlobeNewswire

6 Oct

Impact 4 · · GlobeNewswire

28 Sep

Impact 4 · · Investing.com
Impact 4 · · InvestorsHub
Impact 4 · · GlobeNewswire

22 Sep

Impact 3 · · GlobeNewswire

10 Aug

Impact 3 ·

30 Jun

Impact 3 ·

11 May

Impact 4 · · GlobeNewswire

31 Mar

Impact 4 · · MT Newswires
Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire

12 Mar

Impact 3 ·

4 Mar

Impact 4 · · GlobeNewswire
Impact 3 · · Associated Press Finance

26 Feb

Impact 3 · · GlobeNewswire

28 Jan

Impact 4 · · GlobeNewswire

21 Jan

Impact 4 · · GlobeNewswire

22 Dec

Impact 3 ·

19 Nov

Impact 4 · · GlobeNewswire

17 Nov

Impact 4 · · GlobeNewswire

10 Nov

Impact 3 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

24 Oct

Impact 4 · · Insider Monkey

15 Oct

Impact 4 · · GlobeNewswire

1 Oct

Impact 4 · · clinicaltrialsarena.com

30 Sep

Impact 4 · · GlobeNewswire
stockrow.com/SCYX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com